Zhihua Li

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8140250/publications.pdf

Version: 2024-02-01

29	1,609	361413 20	454955 30
papers	citations	h-index	g-index

30	30	30	2371
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis. Annals of Hematology, 2022, 101, 595-605.	1.8	2
2	circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis. Molecular Cancer, 2022, 21, 24.	19.2	60
3	circCUL2 induces an inflammatory CAF phenotype in pancreatic ductal adenocarcinoma via the activation of the MyD88-dependent NF-Î¹B signaling pathway. Journal of Experimental and Clinical Cancer Research, 2022, 41, 71.	8.6	25
4	Cancer-associated fibroblast-induced lncRNA UPK1A-AS1 confers platinum resistance in pancreatic cancer via efficient double-strand break repair. Oncogene, 2022, 41, 2372-2389.	5.9	21
5	A phase 1b/2 trial of SHR-1701 in combination with gemcitabine and nab-paclitaxel in patients with untreated locally advanced or metastatic pancreatic cancer.. Journal of Clinical Oncology, 2022, 40, e16264-e16264.	1.6	2
6	PDâ€Ł1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced nonâ€ssmall cell lung cancer?. Journal of Gene Medicine, 2021, 23, e3294.	2.8	14
7	A nomogram prognostic index for risk-stratification in diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study. British Journal of Cancer, 2021, 125, 402-412.	6.4	7
8	Neoadjuvant camrelizumab, nab-paclitaxel, and carboplatin in patients with stage IB-IIIA non-small cell lung cancer (NANE-LC): a study protocol of prospective, single-arm, multicenter, phase II study. Journal of Thoracic Disease, 2021, 13, 6468-6475.	1.4	5
9	Novel bloodâ€based tumor mutation algorithm and nomogram predict survival of immune checkpoint inhibitor in nonâ€ssmallâ€ccell lung cancer: Results from two multicenter, randomized clinical trials. Clinical and Translational Medicine, 2020, 10, e53.	4.0	2
10	Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-Î²1/smad2/3 axis in pancreatic cancer. Cancer Letters, 2019, 459, 204-215.	7.2	48
11	Tumor-associated macrophages promote progression and the Warburg effect via CCL18/NF-kB/VCAM-1 pathway in pancreatic ductal adenocarcinoma. Cell Death and Disease, 2018, 9, 453.	6.3	160
12	FEZF1-AS1/miR-107/ZNF312B axis facilitates progression and Warburg effect in pancreatic ductal adenocarcinoma. Cell Death and Disease, 2018, 9, 34.	6.3	48
13	Clinical characteristics and outcomes of Castleman disease: A multicenter study of 185 Chinese patients. Cancer Science, 2018, 109, 199-206.	3.9	50
14	Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer. Cell Death and Disease, 2018, 9, 1065.	6.3	106
15	Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsaâ€miRâ€29bâ€3p in pancreatic ductal adenocarcinoma. Journal of Cellular and Molecular Medicine, 2018, 22, 655-667.	3.6	116
16	Endogenous miRNA Sponge LincRNA-ROR promotes proliferation, invasion and stem cell-like phenotype of pancreatic cancer cells. Cell Death Discovery, 2017, 3, 17004.	4.7	60
17	<scp>HIF</scp>â€2Î± regulates nonâ€canonical glutamine metabolism via activation of <scp>PI</scp>3K/<scp>mTORC</scp>2 pathway in human pancreatic ductal adenocarcinoma. Journal of Cellular and Molecular Medicine, 2017, 21, 2896-2908.	3.6	25
18	LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer by regulating HOXA9. Cancer Letters, 2017, 410, 68-81.	7.2	161

#	Article	IF	Citations
19	A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: New proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases. International Journal of Surgery, 2016, 29, 108-117.	2.7	22
20	Long non-coding RNA LOC389641 promotes progression of pancreatic ductal adenocarcinoma and increases cell invasion by regulating E-cadherin in a TNFRSF10A-related manner. Cancer Letters, 2016, 371, 354-365.	7.2	56
21	The long non-coding RNA HOTAIR affects the radiosensitivity of pancreatic ductal adenocarcinoma by regulating the expression of Wnt inhibitory factor 1. Tumor Biology, 2016, 37, 3957-3967.	1.8	54
22	Gemcitabine plus cisplatin (GP) versus 5-FU plus cisplatin (FP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC): A randomized, open-label, multicenter, phase III trial.. Journal of Clinical Oncology, 2016, 34, 6007-6007.	1.6	1
23	Nanocomplexation of thrombin with cationic amylose derivative for improved stability and hemostatic efficacy. International Journal of Nanomedicine, 2015, 10, 939.	6.7	4
24	Metabolic Phenotypes in Pancreatic Cancer. PLoS ONE, 2015, 10, e0115153.	2.5	34
25	The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer. Journal of Translational Medicine, 2015, 13, 84.	4.4	211
26	Glutamate dehydrogenase is a novel prognostic marker and predicts metastases in colorectal cancer patients. Journal of Translational Medicine, 2015, 13, 144.	4.4	70
27	Inhibition of glutamine metabolism counteracts pancreatic cancer stem cell features and sensitizes cells to radiotherapy. Oncotarget, 2015, 6, 31151-31163.	1.8	76
28	Expression profile of long non-coding RNAs in pancreatic cancer and their clinical significance as biomarkers. Oncotarget, 2015, 6, 35684-35698.	1.8	85
29	Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells. Oncology Reports, 2012, 27, 1879-86.	2.6	35